APR Applied Pharma Research S.A.

56 articles with APR Applied Pharma Research S.A.

• Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU

  7/13/2022

  RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has executed a definitive agreement with Meta Healthcare Ltd., acquiring the worldwide rights, except for the United Kingdom, for a novel dosage form of a prescription drug already approved by the U.S.

• Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients

  3/17/2022

  RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported final data from its clinical trial of nasal spray, Sentinox, in SARS-CoV-2 infected patients.

• Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU

  3/15/2022

  RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has signed a binding term sheet with Meta Healthcare Ltd. to acquire the worldwide commercialization rights, except in the United Kingdom and Ireland, for a novel dosage form of a prescription drug already approved by the U.S. Food and Drug Administration and intended for the treatment of patients with phenylketonuria.

• Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers

  1/24/2022

  Applied Pharmaceutical Science, Inc., has recently announced the Investigational New Drug application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approved by the U.S. Food and Drug Administration.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients

  10/27/2021

  RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported positive interim results from its clinical trial of nasal spray Sentinox in SARS-CoV-2 infected patients, confirming its safety and tolerability.

• Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers

  9/30/2021

  RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported data published in the peer reviewed Journal of Wound Care, indicating that the company's Nexodyn acid-oxidizing solution, developed with APR's proprietary Tehclo technology, was found to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers.

• Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR

  6/29/2021

  RELIEF THERAPEUTICS Holding AG announced that it has signed and closed the definitive agreement to acquire all outstanding shares of APR Applied Pharma Research S.A., a privately held Swiss pharmaceutical company with over 25 years' experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis.

• Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

  5/17/2021

  RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent announcement by APR Applied Pharma Research S.A. regarding the initiation of a pivotal clinical trial with its novel nasal spray, temporarily codenamed APR-AOS2020, a Class III medical device, in patients with mild COVID-19.

• Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR

  5/4/2021

  Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs

• APR Presents New Data at SSIEM Annual Symposium Showing Benefits of PKU GOLIKE® in PKU Management

  9/4/2019

  APR Applied Pharma Research s.a., the Swiss pharma company focused in specialized therapeutic areas and rare diseases, presents at the annual conference of SSIEM latest scientific data confirming benefits of PKU GOLIKE® in PKU management.

• 

  BioSpace's Global Biopharma Roundup: April 4

  4/4/2019

  Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.

• CSC Pharmaceuticals Announces the Launch of the Innovative Migraine and Pain Treatment Developed by APR Applied Pharma Research

  4/3/2019

  APR Applied Pharma Research’s patented formulation of Diclofenac 50 mg powder oral solution for migraine treatment and other pain areas is now available in Russia, promoted and commercialized with the brand Dialrapid by the leading pharmaceutical company CSC Pharmaceuticals.

• Rare Diseases: PKU GOLIKE® Debuts in Germany

  3/21/2019

  PKU GOLIKE®, the brand new generation of Phenylalanine-free medical food for Phenylketonuria dietary management, is now available in Germany and Austria, promoted and distributed directly by APR Applied Pharma Research s.a. through its local subsidiary, APR Deutschland.

• Wound Care: New Clinical Data Show Nexodyn® AOS to Reduce Reinfections and Healing Time in Diabetic Foot Ulcers

  1/30/2019

  Results of a clinical study recently published in the scientific journal “The International journal of Lower Extremity Wound” show Nexodyn® AcidOxidizing Solution, the Tehclo based cleanser for acute and chronic wound care developed by the Swiss pharma company APR Applied Pharma Research S.A., to promote the restart of wound healing process.

• Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia

  12/11/2018

  Nexodyn® AcidOxidizing Solution is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”).

• PKU GOLIKE® Comes to Fruition in Italy

  11/29/2018

  Now available for PKU patients and care givers in Italy, promoted and distributed directly by APR Applied Pharma Research s.a. (APR) through its local subsidiary, APR Italy.

• PKU GOLIKE Debuts at SSIEM 2018 Conference: Science Driven Innovation behind the Medical Food for PKU Management of APR Applied Pharma Research

  9/13/2018

  PKU GOLIKE® is the innovative Phenylalanine (Phe)-free medical food formula for Phenylketonuria (PKU), powered by the patented Physiomimic TechnologyTM.

• 56th Annual Symposium of the SSIEM: APR Will Introduce Its Innovative Phe-Free Medical Food for PKU Management Together with New Original Scientific Data

  8/29/2018

  APR Applied Pharma Research sa is proud to announce it will take part to the forthcoming Annual Symposium of the SSIEM (Society for the Study of Inborn Errors of Metabolism), which will be held in Athens on September 4th-7th.

• Mundipharma and APR Applied Pharma Research Announce a New Alliance for the Distribution of Nexodyn AcidOxidizing Solution in Africa and the Levant

  11/22/2017

  Mundipharma will have exclusive rights to the product in more than 35 African markets and countries.